What is the treatment for gastritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Gastritis

Proton pump inhibitors (PPIs) are the first-line treatment for gastritis, with high-potency options like esomeprazole (20-40 mg twice daily) or rabeprazole (20 mg twice daily) being most effective for symptom relief and mucosal healing. 1, 2

Initial Assessment and Testing

Before initiating treatment, all patients with gastritis must be tested for H. pylori infection using non-invasive methods such as urea breath test or monoclonal stool antigen tests. 1, 2 This is critical because H. pylori-positive gastritis requires eradication therapy in addition to acid suppression to prevent progression to atrophic gastritis and reduce gastric cancer risk. 3, 1

Treatment Based on Etiology

H. pylori-Positive Gastritis

Bismuth quadruple therapy for 14 days is the preferred first-line regimen due to increasing clarithromycin resistance rates. 1, 2 This consists of:

  • High-potency PPI (twice daily)
  • Bismuth subsalicylate
  • Metronidazole
  • Tetracycline

1, 2

When bismuth is unavailable, concomitant 4-drug therapy serves as an alternative first-line option. 1, 2 Triple therapy (PPI + clarithromycin + amoxicillin) should only be used in areas with documented low clarithromycin resistance (<15%). 3, 4

Higher-potency PPIs significantly improve H. pylori eradication rates. 1, 2 The dose-response relationship is well-established, with cure rates increasing from 45% with omeprazole 20 mg once daily to 82.5% with omeprazole 60 mg twice daily when combined with amoxicillin. 5

After completing eradication therapy, confirmation of successful eradication is mandatory using non-serological testing 4+ weeks after treatment completion. 1, 2 Relying solely on symptom resolution without confirming eradication leads to persistent infection and complications. 1

H. pylori-Negative Gastritis

For non-H. pylori gastritis, PPI monotherapy remains the cornerstone of treatment:

  • Esomeprazole: 20-40 mg twice daily (equivalent to 32 mg omeprazole) 1
  • Rabeprazole: 20 mg twice daily (equivalent to 36 mg omeprazole) 1
  • Lansoprazole: 30 mg twice daily (equivalent to 27 mg omeprazole) 1

Avoid pantoprazole when possible due to significantly lower potency (40 mg pantoprazole = only 9 mg omeprazole). 1

Critical timing: PPIs must be taken 30 minutes before meals for optimal effectiveness. 2, 4 Inadequate timing is a common pitfall that reduces treatment efficacy. 1

NSAID-Induced Gastritis

The management algorithm for NSAID-induced gastritis is:

  1. Test for H. pylori and eradicate if positive before initiating or continuing NSAID therapy. 3, 1, 2 H. pylori eradication is mandatory in patients with a history of peptic ulcers who require NSAIDs or aspirin. 3

  2. Discontinue NSAIDs if clinically feasible. 2 If NSAIDs must be continued, add high-dose PPI therapy for gastroprotection. 1, 2

  3. Use the lowest effective NSAID dose for the shortest duration. 1, 2

  4. For aspirin users with ulcer history, the residual risk of peptic ulcer bleeding after successful H. pylori eradication is very low, even without additional gastroprotection. 3

Misoprostol (synthetic PGE1) reduces NSAID-associated gastric ulcers by 74%, but its use is limited by side effects including diarrhea and abdominal pain. 1, 2

Treatment Duration and Follow-up

Standard treatment duration is 4-8 weeks for acute gastritis. 4 If symptoms persist after 8 weeks, an additional 4-week course may be considered. 4

For patients on long-term PPIs who are H. pylori-positive, eradication heals gastritis and prevents progression to atrophic gastritis. 3, 1 Long-term PPI use in H. pylori-positive patients accelerates corpus-predominant gastritis and atrophic changes. 3, 1

Special Populations and Considerations

Autoimmune Gastritis

  • Check antiparietal cell antibodies and anti-intrinsic factor antibodies 1
  • Evaluate for vitamin B-12 and iron deficiencies 1
  • Screen for concomitant autoimmune thyroid disease 1
  • Consider surveillance endoscopy every 3 years for advanced atrophic gastritis 1

Gastric MALT Lymphoma

H. pylori eradication is first-line treatment for low-grade gastric MALT lymphoma (Lugano stage I/II), achieving cure in 60-80% of cases. 3 However, when t(11,18) translocation is present, eradication is usually ineffective and patients require chemotherapy or radiotherapy. 3

Common Pitfalls to Avoid

  • Inadequate PPI dosing or incorrect timing (must be 30 minutes before meals) 1, 2
  • Premature discontinuation of treatment before completing full course 1
  • Failure to test for and eradicate H. pylori when present 1, 2
  • Insufficient antibiotic duration (must be 14 days, not 7-10 days) 2
  • Not confirming H. pylori eradication after treatment 1, 2
  • Failure to evaluate for vitamin B-12 and iron deficiencies in atrophic gastritis 1

Adjunctive Therapy

Antacids provide rapid, temporary symptom relief and can be used on-demand for breakthrough symptoms during PPI therapy. 1, 2 However, they do not heal gastritis and should not be used as monotherapy. 1

budget:token_budget Tokens used this turn: 0 (included in context) + 1600 (response) = 1600 Tokens used total: 1600 / 200000

References

Guideline

Gastritis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gastritis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.